On May 21, 2013, Corcept Therapeutics Incorporated entered into a services agreement with Centric Health Resources, Inc. to provide the exclusive specialty pharmacy and patient services program for drug Korlym, referred to herein as the product, starting early in the third quarter of 2013. Under the terms of the Agreement, subject to certain exceptions, Centric will act as the exclusive specialty pharmacy distributor of the product in the United States for the term of the Agreement. As part of the program, among other services, Centric will provide services related to pharmacy operations; patient intake, access and reimbursement; patient support; claims management and accounts receivable; and data and reporting. Until the transition to Centric is complete, the services referenced above will continue to be provided by the current vendors. The initial term of the Agreement is a period of three years from the initiation of services under the agreement, with successive automatic renewal terms of three years unless either party gives at least 180 days' prior notice of non-renewal.

Corcept Therapeutics Incorporated reported unaudited earnings results for the first quarter ended March 31, 2013. The company reported a net loss of $12.1 million or $0.12 per share, for the first quarter of 2013, compared to a net loss of $11.0 million or $0.13 per share for the same period in 2012. The net loss for the first quarter of 2013 and the corresponding period in 2012 each included significant non-cash expenses of $2.4 million. After adjusting for these non-cash expenses, the company's net loss on a non-GAAP basis was $9.7 million or $0.10 per share, for the first quarter of 2013, compared to $8.6 million or $0.10 per share, for the same period in 2012. Net product sales were 1.7. Loss from operations was $10.9 million against $11 million for the comparable period last year.

Corcept Therapeutics Incorporated announced that they will report Q1, 2013 results on May 02, 2013